{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-086679","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2022-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.349398+00:00","generated_at":"2026-06-26T15:41:35.498975+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NeoGenomics CEO Mallon steps down; Q1 revenue to miss guidance; 2022 outlook withdrawn","bullets":["CEO Mark Mallon steps down effective immediately; Board appoints Lynn Tetrault as Executive Chair, forms Office of the CEO with three executives.","Q1 2022 revenue expected below prior guidance of $118-120M; EBITDA below guidance of ($15)-($12)M, primarily due to higher Clinical Services COGS.","Company withdraws full-year 2022 financial guidance issued Feb 23, 2022; will report Q1 results on Apr 27.","Separation agreement: Mallon receives $775K base salary + $775K target bonus, plus accelerated vesting of certain equity awards.","Board retains Russell Reynolds to conduct CEO search."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-086679","json":"https://secwatch.observer/filing/0001193125-22-086679.json","markdown":"https://secwatch.observer/filing/0001193125-22-086679.md","text":"https://secwatch.observer/filing/0001193125-22-086679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/0001193125-22-086679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/d312815d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T15:41:35.498975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b1dd52ec7","claim":"Mark W. Mallon departed as Chief Executive Officer at NEOGENOMICS INC.","evidence_excerpt":"On March 27, 2022, Mark W. Mallon, Chief Executive Officer (“CEO”) and a member of the Board of Directors (the “Board”) of NeoGenomics, Inc. (the “Company”), stepped down from his positions as CEO and director, effective as of March 28, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/0001193125-22-086679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c535fd148f","claim":"Lynn A. Tetrault was appointed as Executive Chair at NEOGENOMICS INC.","evidence_excerpt":"the Board appointed Lynn A. Tetrault, Esq. the Company’s non-executive Chair of the Board and Chair of the Culture and Compensation Committee, to serve as Executive Chair and the Company’s principal executive officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/0001193125-22-086679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chair"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}